No Prescription |
 |
 | ||
|
Zycolchin Colchicum |
|
| ||
No Prescription » Prescription Drugs 17 » Zycolchin Colchicum Colchicine when used regularly can help prevent a gout attack (e.g. gouty arthritis). Though not a true pain reliever colchicine relieves the pain that occurs with a gout attack. It is believed to act by decreasing the amount of swelling in the affected joint. Buy Zycolchin Colchicum and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Zycolchin Colchicum: Product Type: Prescription Drugs 17 Zycolchin (Colchicum Kolsin Generic Colchicine) Zycolchin (Colchicum Kolsin Generic Colchicine) Colchicum Kolsin Generic Colchicine 0.5mg Colchicum Kolsin Generic Colchicine Zycolchin
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
